Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yin Kan Hwee

Plastic and Reconstructive Surgery Ft Lauderdale, FL Medical Doctor

NPI 1932319076 CMS profile 873762

407 Se 24Th St, Ft Lauderdale, FL 33316

Open in the dashboard

General payments

$9,086

202 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yin Kan Hwee of Ft Lauderdale, FL is reported in the CMS Open Payments database as having received $9,086 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $986 28
2024 General $2,111 28
2023 General $1,160 29
2022 General $1,323 35
2021 General $785 27
2020 General $710 18
2019 General $2,012 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yin Kan Hwee
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Yin Kan Hwee were reported at $986. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Yin Kan Hwee Plastic and Reconstructive Surgery median Middle half National median
2019 $2,012 $335 $121–$1,264 $163
2020 $710 $162 $57–$417 $114
2021 $785 $245 $89–$735 $132
2022 $1,323 $325 $120–$932 $149
2023 $1,160 $343 $129–$999 $160
2024 $2,111 $390 $141–$1,085 $164
2025 $986 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. TELA Bio, Inc. $1,836 59 payments
  2. Mentor Worldwide LLC $1,764 22 payments
  3. Musculoskeletal Transplant Foundation Inc. $1,161 11 payments
  4. Allergan Inc. $731 19 payments
  5. Medical Device Business Services, Inc. $524 2 payments
  6. Integra LifeSciences Corporation $415 15 payments
  7. AbbVie, Inc. $406 11 payments
  8. AxoGen $313 8 payments
  9. Sientra, Inc. $270 9 payments
  10. PolyNovo North America LLC $214 4 payments
  11. Other $1,451 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,367 198 payments
  2. Travel and Lodging $1,720 4 payments
Products named General payments · program years 2019–2025
  1. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $1,446 46 payments
  2. MENTOR MemoryGel Resterilizable Gel Sizer $810 13 payments
  3. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $379 10 payments
  4. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $355 9 payments
  5. NATRELLE $352 9 payments
  6. OviTex 2S $294 7 payments
  7. AMNIOEXCEL $290 11 payments
  8. FLOWABLE $290 11 payments
  9. INTEGRA WOUND MATRIX (IWM) $290 11 payments
  10. IDRT $290 11 payments
  11. Other $3,971 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

446

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$3,344

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

11%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 132 $1,271
Celecoxib Generic 67 $864
Gabapentin Generic 89 $324
Clindamycin Hcl Generic 27 $300
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 49 $241
Doxycycline Hyclate Generic 21 $132
Tramadol Hcl Generic 50 $107
Scopolamine Generic 11 $105

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$62,163

Medicare's payments for the services billed

Medicare patients

83

Average age 73

Services billed

216

40 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Arthritis 45%
Ischemic heart disease 42%
Chronic kidney disease 36%
Cancer 36%
Atrial fibrillation 23%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record